Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
Copenhagen-based biotech firm Genmab (CSE:GMAB) A/S (NASDAQ:GMAB) reported on Tuesday a series of transactions as part of its share buy-back program. The disclosure, filed with the SEC, follows the company’s commitment to repurchase shares between June 2 and June 6, 2025.
The transactions were carried out under the program initiated by Genmab, which was previously announced and detailed in its registration statements on Form S-8. The company’s buy-back program is part of a strategy to adjust its capital structure and return value to shareholders.
According to the filing, the specifics of the shares repurchased during the first week of June, including the number of shares acquired and the prices paid, were provided in Exhibit 99.1(a) of the 6-K form. This exhibit is incorporated by reference into Genmab’s registration statements and is part of the official document from the date of filing, superseding any subsequent documents or reports filed or furnished.
The share buy-back program aligns with Genmab’s broader financial management policies and is conducted within the parameters of regulatory requirements. The company, known for its work in pharmaceutical preparations, operates within the stringent guidelines of both the Danish financial authorities and international bodies such as the SEC.
This report on Form 6-K will be considered incorporated by reference into Genmab’s registration statements and will be a part thereof from the date of filing, to the extent not superseded by documents or reports subsequently filed or furnished.
The SEC filing also includes the signature of Anthony Pagano, Executive Vice President & Chief Financial Officer of Genmab, who executed the report on behalf of the registrant.
Investors and stakeholders can access details of the share buy-back transactions by referring to the exhibits listed in the SEC filing. The company’s actions reflect its ongoing efforts to manage its capital efficiently and maximize shareholder value. The information in this article is based on a press release statement from Genmab A/S.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.